Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.48 |
| ▸ | HTR7 | P34969 | 6/20 | 0.48 |
| ▸ | HTR6 | P50406 | 6/20 | 0.48 |
| ▸ | CCR5 | P51681 | 10/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2449653 | 0.90 | LTA4H (0.47) | HTR1AHTR7HTR6MCHR1LTA4H | |
| SCHEMBL2450324 | 0.89 | LTA4H (0.44) | HTR1AHTR7HTR6MCHR1LTA4H | |
| SCHEMBL3507285 | 0.87 | HTR1A (0.52) | HTR1AHTR7HTR6CCR5MCHR1 | |
| SCHEMBL2447782 | 0.86 | HTR1A (0.49) | HTR1AHTR7HTR6CCR5MCHR1 | |
| SCHEMBL2451918 | 0.82 | CCR5 (0.50) | HTR1AHTR7HTR6CCR5MCHR1 | |
| SCHEMBL12581221 | 0.81 | CXCR3 (0.42) | HTR1AHTR7HTR6CCR5MCHR1 | |
| SCHEMBL3507206 | 0.81 | MCHR1 (0.48) | HTR1AHTR7HTR6CCR5MCHR1 | |
| SCHEMBL2449343 | 0.80 | HTR1A (0.50) | HTR1AHTR7HTR6CCR5MCHR1 | |
| SCHEMBL12581219 | 0.80 | SIGMAR1 (0.52) | HTR1AHTR7HTR6MCHR1CYP3A4 | |
| SCHEMBL2451505 | 0.80 | HTR1A (0.46) | HTR1AHTR7HTR6CCR5MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364982-A1 | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof | ONO Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-7498323-B2 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1619193-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | CCR1, CCR7, CCR3 | HTR1A 2467/4885HTR7 2589/4885HTR6 2806/4885 |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | CCR1, CCR7, CCR3 | HTR1A 2467/4885HTR7 2589/4885HTR6 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.